Zobrazeno 1 - 10
of 949
pro vyhledávání: '"Breedveld, F C"'
Autor:
Breedveld, F. C.
Publikováno v:
Lancet. 2/26/2000, Vol. 355 Issue 9205, p735-740. 6p. 1 Color Photograph, 1 Chart.
Autor:
Buch, M. h., Smolen, J. s., Betteridge, N., Breedveld, F. c., Burmester, G., Dorner, T., Ferraccioli, G., Gottenberg, J. e., Isaacs, J., Kvien, T. k., Mariette, X., Martin Mola, E., Pavelka, K., Tak, P. p., Van Der Heijde, D., Van Vollenhoven, R. f., Emery, P., Carbonell Abello, Rituximab Consensus Expert Committee (., Bukhari, M., Burkhardt, H., Combe, B., Gomez Reino Carnota, J. j., Barile Fabris, L., Klareskog, L., Marenco De La Fuente, J. l., Montecucco, C. m., Mikkel, Ostergaard, Pascual Gomez, E., Sanmarti Sala, R., Tony, Hp, Valesini, Guido, Van Laar, J., Van Riel, P.
Publikováno v:
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, 70(6), 909-920. BMJ Publishing Group
Annals of the Rheumatic Diseases, 70(6), 909-920
Annals of the Rheumatic Diseases, 70(6), 909-920. BMJ Publishing Group
Annals of the Rheumatic Diseases, 70(6), 909-920
BackgroundSince initial approval for the treatment of rheumatoid arthritis (RA), rituximab has been evaluated in clinical trials involving various populations with RA. Information has also been gathered from registries. This report therefore updates
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3257deccc14615d7a9a4f74194772c42
https://doi.org/10.1136/ard.2010.144998
https://doi.org/10.1136/ard.2010.144998
Publikováno v:
Clinical & Experimental Immunology. Sep1984, Vol. 57 Issue 3, p557-563. 7p.
Autor:
Lobatto, S.1, Breedveld, F. C.2, Camps, J. A. J.3, Pauwels, E. K. J.3, Westedt, Marie-Louise2, Daha, M. R.1, Van Es, L. A.1
Publikováno v:
Clinical & Experimental Immunology. Mar1987, Vol. 67 Issue 3, p461-466. 6p.
Autor:
Smolen, J. S., Keystone, E. C., Emery, P., Breedveld, F. C., Betteridge, N., Burmester, G. R., Dougados, M., Ferraccioli, G., Jaeger, U., Klareskog, L., Kvien, T. K., Martin Mola, E., Pavelka, K., Carbonell, Jordi, Combe, Bernard, Cutolo, Maurizio, Dörner, Thomas, Gause, Angela, Gomez Reino, Juan, Fernandes, Carlos Gonzales, Isaacs, John D., Marenco, José Luis, Mariette, Xavier, Matucci Cerinic, Marco, Montecucco, Carlo Maurizio, Nüßlein, Hubert, Østergaard, Mikkel, Pascual, Eliseo, Van Riel, Piet, Rubbert, Andrea, Sanmarti, Raimon, Sekanecz, Zoltan, Tak, Paul Peter, Tony, Hans Peter, Valesini, Guido, VALENTINI, Gabriele
A large number of experts experienced in the treatment of rheumatoid arthritis were involved in formulating a consensus statement on the use of B cell-targeted treatment with rituximab in patients with rheumatoid arthritis. The statement was supporte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd64979d2d74b5250e7190eaf5c2027f
https://europepmc.org/articles/PMC1798500/
https://europepmc.org/articles/PMC1798500/
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Breedveld FC (AUTHOR), Breedveld, F C1 (AUTHOR)
Publikováno v:
Lancet. 10/13/2001, Vol. 358 Issue 9289, p1198-1200. 3p.
Publikováno v:
Annals of the rheumatic diseases, 65(1). BMJ Publishing Group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::aad518ac56c628553714c9cf85544466
https://pure.amc.nl/en/publications/updated-consensus-statement-on-biological-agents-specifically-tumour-necrosis-factor-alpha-tnf-alpha-blocking-agents-and-interleukin1-receptor-antagonist-il1ra-for-the-treatment-of-rheumatic-diseases-2005-vol-64-pg-2-2005(ae2d9ccf-7594-4e03-9c27-a87332049b85).html
https://pure.amc.nl/en/publications/updated-consensus-statement-on-biological-agents-specifically-tumour-necrosis-factor-alpha-tnf-alpha-blocking-agents-and-interleukin1-receptor-antagonist-il1ra-for-the-treatment-of-rheumatic-diseases-2005-vol-64-pg-2-2005(ae2d9ccf-7594-4e03-9c27-a87332049b85).html
Autor:
Furst, Daniel E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Bijlsma, JWJ, Dougados, M, Emery, P, Keystone, E C, Klareskog, L, Mease, P J
Publikováno v:
Furst, Daniel E; Breedveld, F C; Kalden, J R; Smolen, J S; Burmester, G R; Bijlsma, JWJ; et al.(2004). Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNF alpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Annals of the Rheumatic Diseases, 63, 2-12. UCLA: Retrieved from: http://www.escholarship.org/uc/item/8hk2r0bz
As in previous years, the consensus group to consider the use of biological agents was constituted by rheumatologists from the Universities of Erlangen, Leiden, and Vienna in Europe in cooperation with other Universities in the USA, Canada, and Europ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::6713ab4ed3b53d63397cba8ae1ce0279
http://www.escholarship.org/uc/item/8hk2r0bz
http://www.escholarship.org/uc/item/8hk2r0bz
Publikováno v:
Clinical and experimental rheumatology, 17(6 Suppl 18), S103-S104. Clinical and Experimental Rheumatology S.A.S.
Antimalarials are attractive candidates for combination therapy. In vitro experiments have revealed a synergistic mode of action of cyclosporine and chloroquine which could not, however, be confirmed in a clinical trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::e1fd87a4c25061fcd922b087af610d40
https://pure.amc.nl/en/publications/combination-cyclosporine-and-hydroxychloroquine-in-rheumatoid-arthritis(41bc9872-40b0-4fa7-99e2-d440327c165f).html
https://pure.amc.nl/en/publications/combination-cyclosporine-and-hydroxychloroquine-in-rheumatoid-arthritis(41bc9872-40b0-4fa7-99e2-d440327c165f).html